Shimokawa H - Search Results

1

Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target.

Kagaya Y, Asaumi Y, Wang W, Takeda M, Nakano M, Satoh K, Fukumoto Y, Shimokawa H. Kagaya Y, et al. Among authors: shimokawa h. Tohoku J Exp Med. 2012 Jun;227(2):83-91. doi: 10.1620/tjem.227.83. Tohoku J Exp Med. 2012. PMID: 22688525 Free article. Review.

2

Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor.

Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, Takayanagi T, Egashira K, Takeshita A. Shimokawa H, et al. J Clin Invest. 1996 Feb 1;97(3):769-76. doi: 10.1172/JCI118476. J Clin Invest. 1996. PMID: 8609234 Free PMC article.

3

Altered serotonin receptor subtypes mediate coronary microvascular hyperreactivity in pigs with chronic inhibition of nitric oxide synthesis.

Kadokami T, Egashira K, Kuwata K, Fukumoto Y, Kozai T, Yasutake H, Kuga T, Shimokawa H, Sueishi K, Takeshita A. Kadokami T, et al. Among authors: shimokawa h. Circulation. 1996 Jul 15;94(2):182-9. doi: 10.1161/01.cir.94.2.182. Circulation. 1996. PMID: 8674177

4

Slowing of ventricular rate quickly improved ventricular dysfunction and exercise intolerance in patients with chronic atrial tachycardia.

Fukumoto Y, Urabe Y, Shimokawa H, Chishaki-Suyama A, Takeshita A. Fukumoto Y, et al. Among authors: shimokawa h. Fukuoka Igaku Zasshi. 1996 Dec;87(12):274-7. Fukuoka Igaku Zasshi. 1996. PMID: 9011110

5

Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.

Shimokawa H. Shimokawa H. J Cardiovasc Pharmacol. 2002 Mar;39(3):319-27. doi: 10.1097/00005344-200203000-00001. J Cardiovasc Pharmacol. 2002. PMID: 11862109 Review.

6

Augmented vasodilator response to L-arginine after coronary angioplasty may attenuate restenosis.

Fukumoto Y, Urabe Y, Kubo T, Kaku T, Egashira K, Shimokawa H, Takeshita A. Fukumoto Y, et al. Among authors: shimokawa h. Heart Vessels. 2002 Jul;16(5):171-4. doi: 10.1007/s003800200017. Heart Vessels. 2002. PMID: 12181589 Clinical Trial.

7

Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms.

Matsumoto Y, Uwatoku T, Oi K, Abe K, Hattori T, Morishige K, Eto Y, Fukumoto Y, Nakamura K, Shibata Y, Matsuda T, Takeshita A, Shimokawa H. Matsumoto Y, et al. Among authors: shimokawa h. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):181-6. doi: 10.1161/01.ATV.0000105053.46994.5B. Epub 2003 Oct 30. Arterioscler Thromb Vasc Biol. 2004. PMID: 14592842

8

Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers.

Ito A, Fukumoto Y, Shimokawa H. Ito A, et al. Among authors: shimokawa h. J Cardiovasc Pharmacol. 2004 Oct;44(4):480-5. doi: 10.1097/01.fjc.0000141473.29254.62. J Cardiovasc Pharmacol. 2004. PMID: 15454857

9

Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery.

Inokuchi K, Ito A, Fukumoto Y, Matoba T, Shiose A, Nishida T, Masuda M, Morita S, Shimokawa H. Inokuchi K, et al. Among authors: shimokawa h. J Cardiovasc Pharmacol. 2004 Sep;44(3):275-7. doi: 10.1097/01.fjc.0000134775.76636.3f. J Cardiovasc Pharmacol. 2004. PMID: 15475822

10

[Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report].

Hiroki J, Fukumoto Y, Shimokawa H, Hirooka Y, Takeshita A. Hiroki J, et al. Among authors: shimokawa h. J Cardiol. 2004 Oct;44(4):161-4. J Cardiol. 2004. PMID: 15532247 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,130 results

Search Page

Filters